NPS Logo


August 4, 2010
NPS Pharmaceuticals Reports Second Quarter 2010 Financial Results and Two Phase 3 Registration Programs on Track with Stated Timelines

July 29, 2010
NPS Pharmaceuticals to Present at Upcoming Conferences

more news


STEPS

Now enrolling patients in a Phase 3 clinical trial evaluating GATTEX™ (teduglutide) for reducing parenteral nutrition (PN) dependence in short-bowel syndrome (SBS) patients.  To learn more click here.

REPLACE

Now enrolling patients in a Phase 3 clinical trial, known as REPLACE, evaluating NPSP558 (recombinant full-length human parathyroid hormone 1-84) for the treatment of hypoparathyroidism.  To learn more click here